Sareum Holdings plc (LON:SAR – Get Free Report) shares rose 1.9% on Monday . The company traded as high as GBX 27 ($0.34) and last traded at GBX 27 ($0.34). Approximately 264,022 shares changed hands during trading, a decline of 61% from the average daily volume of 674,550 shares. The stock had previously closed at GBX 26.50 ($0.34).
Sareum Price Performance
The stock has a fifty day moving average price of GBX 26.31 and a two-hundred day moving average price of GBX 30.49. The company has a market cap of £29.15 million, a P/E ratio of -450.00 and a beta of -1.08.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Further Reading
- Five stocks we like better than Sareum
- Basic Materials Stocks Investing
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Investing In Automotive Stocks
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- How to Invest in Biotech Stocks
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
